cjc 1295 vs bpc 157 bpc-157 Ipamorelin vs CJC 1295 FDA panel votes to ease

In clinical use, the most commonly reported side effects are: Mild injection site redness or swelling (resolves within hours) Occasional lightheadedness following injection (less common, position-dependent) Temporary nausea with oral administration in some patients Who should not use BPC-157: Patients with active cancer or a history of cancer should discuss BPC-157 carefully with their oncologist before use angiogenic peptides theoretically could support tumor vascularity, though no evidence of this has been demonstrated in animals

Her question as to how they plan to deal with her returning symptoms remains unanswered

K., Low, P

Disclaimer: Insurance company policies change from time to time